Despite the low to moderate methodological quality according to the RoB tool, presented in Supplementary Material, and the lack of independent statistics, the evidence presented in this systematic review still indicates NOS inhibition as a promising strategy for (additional) neuroprotection in human neonates after perinatal asphyxia. The gene discussed is NOS2; the disease is asphyxia.